Therapeutic approaches to respiratory diseases excluding asthma:Trends from the patent literature 1997 - 2000

Bibliography

• IMS: Health Drug Monitor (January 2000).
   Google Scholar
• NORMAN P: Pulmonary Diseases. FT Management Reports (1999).
   Google Scholar
• ••Comprehensive overview of both research efforts and market developments.
   Google Scholar
• COUSINS RL: Therapeutic approaches to the treatment of asthma: 1997–2000. Exp. Opin. Ther. Patents (2001) 11 :In press.
   Google Scholar
• •Comprehensive review of recent patent literature in the asthma field.
   Google Scholar
• NORMAN P: Therapeutic approaches to the treatment of respiratory diseases excluding asthma; trends from the patent literature 1993–1997. Exp. Opin. Ther. Patents (1998) 8:1-8. The previous review in this series.
   Google Scholar
• NORMAN P: COPD, new developments & therapeutic opportunities. Drug News Perspect. (1998) 11 :431–437.
   PubMedGoogle Scholar
• BARNES PJ: Chronic obstructive lung disease, new opportunities for drug development. Trends Pharmacol. ScI (1998) 19:415–424.
   PubMed Web of Science ®Google Scholar
• •The perspective from a leading chest physician.
   Google Scholar
• HAY DWP: Chronic obstructive pulmonary disease, emerging therapies. Curr. Opin. Chem. Biol. 4:412–419 (2000).
   PubMed Web of Science ®Google Scholar
• •The perspective from the pharmaceutical industry.
   Google Scholar
• AMERICAN THORACIC SOCIETY: Standards for the diagnosis and care of patients with chronic obstruc-tive pulmonary disease. Am. J. Resp. Grit. Care Med. (1995) 149:S77–5120.
   Google Scholar
• LECKIE M, J, BRYER SA, HANSEL TT, BARNES PJ: Novel therapy for COPD. Exp. Opin. Invest. Drugs (1999) 9 :3–23.
   Web of Science ®Google Scholar
• BONNERT RV, BROWN, RC, CHAPMAN D et al.: Dual D2-receptor and I32-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(31/)-one analogues. J Med. Chem. (1998) 41:4915–4917.
   Google Scholar
• •Outlines the rationale for a novel approach.
   Google Scholar
• ASTRAZENECA: Press Release (8 May 2000).
   Google Scholar
• ALABASTER V: Discovery and development of selective M3 antagonists for clinical use. Life Sci. (1997) 60:1053–1060.
   PubMed Web of Science ®Google Scholar
• NORMAN P PDE4 inhibitors: sustained patenting activity as drugs near the market. Exp. Opin. Ther. Patents (2000) 9:1415–1428.
   Google Scholar
• SMITHKLINE BEECHAM: Annual Report (1999).
   Google Scholar
• SEWARD EM, SWAIN CJ: Neurokinin antagonists. Exp. Opin. Ther. Patents (1999) 9:571–582.
   Web of Science ®Google Scholar
• GIARDINA GAM, RAVEGLIA LF: Neurokinin-3 receptor antagonists. Exp. Opin. Ther. Patents (1997) 4:307–323.
   Google Scholar
• SAUNDERS J, TARBY CM: Opportunities for novel therapeutic agents acting at chemokine receptors. Drugs Discov. Today (1999) 4:80–92.
   PubMed Web of Science ®Google Scholar
• OLIVIER KN, BENNETT WD, HOHNEKER KW et al.: Acute safety and effects on mucociliary clearance of aerosol- ized uridine 5t-triphosphateamiloride in normalhuman adults. Am. J. Resp. Crit. Care Med. 154:217–23.
   Google Scholar
• REPINE JE, BAST A, LANKHORST I: Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group 1996. Am. J. Respir. Crit. Care Med. (1997) 156:341–357.
   Google Scholar
• STOCKLEY RA: The role of proteinases in the pathogenesis of chronic bronchitis. Am. J Respir. Crit. Care Med. (1994) 150:S109–S113.
   Web of Science ®Google Scholar
• TETLEY TD: Matrix metalloproteinases; a role in emphysema. Thorax (1997) 52:495.
   PubMed Web of Science ®Google Scholar
• CHAPMAN HA, RIESE RJ, SHI GP: Emerging roles for cysteine proteases in human biology. Ann. Rev. Physiol. (1997) 59:63–88.
   PubMed Web of Science ®Google Scholar
• PARDO A, SELMAN M: Proteinase-antiproteinase imbalance in the pathogenesis of emphysema: the role of metalloproteinases in lung damage. Histol Histopa-thol (1999) 14(1):227–233.
   PubMed Web of Science ®Google Scholar
• MEYER KC, CORNWELL RD, LOVE RB: Short- and long-term results after lung volume reduction surgery. Curr. Opin. Pulm. Med. (2000) 6:116–21.
   PubMedGoogle Scholar
• A novel structural motif for serine protease inhibitors. Exp. Opin. Ther. Patents (1999) 9:1133–1137.
   Google Scholar
• ASTRA ZENECA: R&D Presentation (December 1999).
   Google Scholar
• METZ WA, PEET NP: Inhibitors of human neutrophil elastase as a potential treatment for inflammatory diseases. Exp. Opin. Ther. Patents (1999) 9:851–868.
   Web of Science ®Google Scholar
• SKILES JW, JENG AY: Therapeutic promises of leukocyte elastase and macrophage metalloelastase inhibitors for the treatment of pulmonary emphysema. Exp. Opin. Ther. Patents (1999) 9:869–895.
   Web of Science ®Google Scholar
• TORPHY TJ: Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am. J Respir. Crit. Care Med. (1998) 157:351–370.
   PubMed Web of Science ®Google Scholar
• MASSARO GD, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. (1997) 3(6):675–677.
   PubMed Web of Science ®Google Scholar
• ••The first suggestion that alveolar damage might berepairable.
   Google Scholar
• MASSARO GD, MASSARO D: Retinoic acid treatment partially rescues failed septation in rats and in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. (2000) 278 (5):L955–960.
   Web of Science ®Google Scholar
• TEPPER J, PFEIFFER J, ALDRICH M et al.: Can retinoic acid ameliorate the physiologic and morphologic effects of elastase instillation in the rat? (2000) Chest 117 (Suppl. 1):242S–4S.
   Google Scholar
• BELLONI PN, GARVIN L, MAO CP et al.: Effects ofall-trans-retinoic acid in promoting alveolar repair. Chest (2000) 117 (Suppl. 1):235S–41S.
   Google Scholar
• ELBORN JS, SHALE DJ, BRITTON JR: Cystic fibrosis, current population and survival estimates to the year 2000. Thorax (1992) 46:881–85.
   Web of Science ®Google Scholar
• GUGGINO WB: Cystic fibrosis and the salt controversy. (1999) Ce// 96:607–610.
   Google Scholar
• SHAH PL: Update on clinical trials in the treatment of pulmonary disease in patients with cystic fibrosis. (1999) Exp. Opin. Invest. Drugs 8:1917–1927.
   Google Scholar
• MASON RJ, SCHVVARZ MI, HUNNINGHAKE GW, MUSSON RA: NHLBI workshop summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present and future. Am. J. Resp. Crit. Care Med. (1999) 160:1771–1777.
   Google Scholar
• COOPER JA: Pulmonary fibrosis, pathways are slowlycoming into light. Am. J. Resp. Cell. Mol. Biol. (2000) 22:520–523.
   PubMed Web of Science ®Google Scholar
• EGAN JJ: New treatments for pulmonary fibrosis? Lancet (1999) 354: 1839-1840.
   Google Scholar
• PAINE R, WARD PA: Cell adhesion molecules and pulmonary fibrosis. Am. J Med. (1999) 107:268–279.
   PubMed Web of Science ®Google Scholar
• GAULDIE J, SIME PJ, XING Z et al: Transforming growth factor-beta gene transfer to the lung induces myofibro-blast presence and pulmonary fibrosis. Curr. Top. Pathol. (1999) 93:35–45.
   PubMedGoogle Scholar
• PINES M, NAGLER A: Halofuginone: a novel antifibrotic therapy. Gen. Pharmacol (1998) 30:445–450.
   PubMedGoogle Scholar
• HUDSON LD: Epidemiology of acute lung injury and ARDS. Chest (1999) 116 (Suppl.):74S–82S.
   Google Scholar
• LEWANDOWSKI K: Epidemiological data challenge ARDS/ALI definition. Intensive Care Med. (1999) 25 (9):884–886.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, MATTHAY MA, DINARELLO CA et al.: Consensus conference definitions for sepsis, septic shock, acute lung injury and acute respiratory distress syndrome: time for a reevaluation. Crit. Care Med. (2000) 28(0:232–235.
   PubMed Web of Science ®Google Scholar
• WYNCOLL DL, EVANS TW: Acute respiratory distress syndrome. Lancet (1999) 354 (9177):497–501.
   PubMed Web of Science ®Google Scholar
• DOERSCHUK CM, MIZGERD JP, KUBO H et al.: Adhesion molecules and cellular biomechanical changes in acute lung injury. Chest (1999) 116 (Suppl.):37S–43S.
   Google Scholar
• BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Exp. Opin. Ther. Patents (2000) 10:28–37.
   Web of Science ®Google Scholar
• DOWNEY GP, DONG Q, KRUGER J et al.: Regulation of neutrophil activation in acute lung injury. Chest (1999) 116 (Suppl.):46S–54S.
   Google Scholar
• WEINBERGER B, HECK DE, LASKIN DL, LASKIN JD: Nitric oxide in the lung: therapeutic and cellular mechanisms of action. PharmacoL Ther. (1999) 84 (3):401–411.
   PubMed Web of Science ®Google Scholar
• COMPTON CH, GUBB J, CEDAR E et al.: Ariflo (5B207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD. Am. J Respir. Crit. Care Med (1999) 159:A806.© Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001) 11(2)
   Google Scholar
• NORMAN P: PDFA inhibitors 1999. Exp. Opin. Ther. Patents (1999) 9:1101–1118.
   Web of Science ®Google Scholar
• www.goldcopd.com Global Initiative for Chronic Obstructive Lung Disease (June 2000). Peter Norman
   Google Scholar